Histone Acetyltransferase Inhibitor IV, CPTH2, HAT Inhibitor IV, Cyclopentylidene-(4-(4ʹ-chlorophenyl)thiazol-2-yl)hydrazone, GCN5 Inhibitor II, N-acetyltransferase 10 Inhibitor I, NAT10 Inhibitor I
A cell-permeable thiazolyl-hydrazone compound that inhibits the acetylation of histone H3 by recombinant human Gcn5 in a substrate-competive manner, while exhibiting little activity against rhGcn5 autoacetylation. Although functional knockout of Gcn5 in Saccharomyces cerevisiae by genetic deletion or by CPTH2 treatment is not detrimental to the survival of the budding yeast, CPTH2 treatment is shown to inhibit the growth of yeast strain genetically deleted of Gcn5, but not strains deleted of Elp3 or Sas2.
包装
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
再構成
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
その他情報
Larrieu, D., et al. 2014. Science, 344, 527. Chimenti, F., et al. 2009. J. Med. Chem.52, 530.
法的情報
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Cancer research communications, 2(6), 402-416 (2023-01-24)
The emergence of treatment resistance significantly reduces the clinical utility of many effective targeted therapies. Although both genetic and epigenetic mechanisms of drug resistance have been reported, whether these mechanisms are stochastically selected in individual tumors or governed by a